APA-viite

Cortes, J., Lipton, J. H., Rea, D., Digumarti, R., Chuah, C., Nanda, N., . . . Kantarjian, H. (2012). Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood.

Chicago-tyylinen lähdeviittaus

Cortes, Jorge, et al. "Phase 2 Study of Subcutaneous Omacetaxine Mepesuccinate After TKI Failure in Patients With Chronic-phase CML With T315I Mutation." Blood 2012.

MLA-viite

Cortes, Jorge, et al. "Phase 2 Study of Subcutaneous Omacetaxine Mepesuccinate After TKI Failure in Patients With Chronic-phase CML With T315I Mutation." Blood 2012.

Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.